These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22811580)

  • 1. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
    Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
    Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
    Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
    Ahsan S; Ge Y; Tainsky MA
    Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.
    Brundage ME; Tandon P; Eaves DW; Williams JP; Miller SJ; Hennigan RH; Jegga A; Cripe TP; Ratner N
    Oncogene; 2014 Dec; 33(49):5626-36. PubMed ID: 24509877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
    Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
    Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.
    Katz D; Lazar A; Lev D
    Expert Rev Mol Med; 2009 Oct; 11():e30. PubMed ID: 19835664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
    Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
    J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
    Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
    J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.
    Patel AV; Chaney KE; Choi K; Largaespada DA; Kumar AR; Ratner N
    EBioMedicine; 2016 Jul; 9():110-119. PubMed ID: 27333032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
    Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
    Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.